Jeffrey Zhang

3.1k total citations · 1 hit paper
50 papers, 1.9k citations indexed

About

Jeffrey Zhang is a scholar working on Neurology, Molecular Biology and Oncology. According to data from OpenAlex, Jeffrey Zhang has authored 50 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Neurology, 7 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Jeffrey Zhang's work include Amyotrophic Lateral Sclerosis Research (6 papers), Sleep and related disorders (6 papers) and Parkinson's Disease Mechanisms and Treatments (4 papers). Jeffrey Zhang is often cited by papers focused on Amyotrophic Lateral Sclerosis Research (6 papers), Sleep and related disorders (6 papers) and Parkinson's Disease Mechanisms and Treatments (4 papers). Jeffrey Zhang collaborates with scholars based in United States, Canada and Japan. Jeffrey Zhang's co-authors include Sherry Wang‐Weigand, Thomas Roth, David Seiden, Stephen M. Sainati, Jay R. Lieberman, Roberto Iglesias, Marc H. Hedrick, Prosper Benhaim, Mandar A. Aras and Sanjiv J. Shah and has published in prestigious journals such as Nature, Circulation and Nature Communications.

In The Last Decade

Jeffrey Zhang

47 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fully Automated Echocardiogram Interpretation in Clinical Practice

2018 568 citations Jeffrey Zhang, Sravani Gajjala et al. Circulation profile →

Peers

Countries citing papers authored by Jeffrey Zhang

Since Specialization

Citations

This map shows the geographic impact of Jeffrey Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Zhang more than expected).

Fields of papers citing papers by Jeffrey Zhang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Zhang. The network helps show where Jeffrey Zhang may publish in the future.

Co-authorship network of co-authors of Jeffrey Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Zhang. A scholar is included among the top collaborators of Jeffrey Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Zhang. Jeffrey Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	How short peptides disassemble tau fibrils in Alzheimer’s disease	Nature	Ke Hou, P. Ge et al.	3
2	Safety and efficacy of continuous infusion terlipressin (BIV201): A phase 2 trial in patients with decompensated cirrhosis and refractory ascites	Liver Transplantation	Jasmohan S. Bajaj, Ethan M. Weinberg et al.	2
3	The effects of a smoking cessation intervention on mortality after a 32.5-year follow-up period: a randomized clinical trial	American Journal of Epidemiology	Jeffrey Zhang, Dylan S. Small et al.	0
4	An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's disease	Frontiers in Neuroscience	Christopher L. Reading, Jiayan Yan et al.	1
5	Efficacy of Radicava® IV (intravenous edaravone) in subjects with differing trajectories of disease progression in amyotrophic lateral sclerosis: Use of a novel statistical approach for post hoc analysis of a pivotal phase 3 clinical trial	Journal of the Neurological Sciences	Erik P. Pioro, Benjamin Rix Brooks et al.	4
6	Enhanced phosphate anion flux through single-ion, reverse-selective mixed-matrix cation exchange membrane	SHILAP Revista de lepidopterología	Sungsoon Kim, Jeffrey Zhang et al.	1
7	MRI-Based Brain Volume Scoring in Cerebral Malaria Is Externally Valid and Applicable to Lower-Resolution Images	American Journal of Neuroradiology	Manu S. Goyal, Jeffrey Zhang et al.	1
8	Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis	EClinicalMedicine	Benjamin Rix Brooks, James D. Berry et al.	32
9	Auxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trial	Critical Care	Charles Bruen, Edward A. Michelson et al.	25
10	Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]	PLoS ONE	Benjamin Rix Brooks, Terry Heiman‐Patterson et al.	17
11	Pan-caspase inhibition as a potential host-directed immunotherapy against MRSA and other bacterial skin infections	Science Translational Medicine	Martin P. Alphonse, Roger V. Ortines et al.	33
12	Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial	Critical Care	Joseph M. Miller, Charles Bruen et al.	55
13	PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen®): Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers	BioDrugs	Faith D. Ottery, Stuart Harris et al.	10
14	Fully Automated Echocardiogram Interpretation in Clinical Practice breakdown →	Circulation	Jeffrey Zhang, Sravani Gajjala et al.	568
15	A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer	Supportive Care in Cancer	Morten Schiødt, Saroj Vadhan‐Raj et al.	44
16	Pharmacodynamic and Pharmacokinetic Equivalences of Epoetin Hospira and Epogen® After Multiple Subcutaneous Doses to Healthy Male Subjects	Clinical Therapeutics	Dennis J. Stalker, Jeffrey Zhang et al.	6
17	Safety and Subjective Sleep Effects of Ramelteon Administration in Adults and Older Adults With Chronic Primary Insomnia	The Journal of Clinical Psychiatry	Gary S. Richardson, Gary Zammit et al.	40
18	The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease	Sleep And Breathing	Meir H. Kryger, Thomas Roth et al.	43
19	Effect of Ramelteon, a selective MT1/MT2-receptor agonist, on respiration during sleep in mild to moderate COPD	Sleep And Breathing	Meir H. Kryger, Sherry Wang‐Weigand et al.	22
20	Genetically Modified Human Derived Bone Marrow Cells for Posterolateral Lumbar Spine Fusion in Athymic Rats	Spine	Roberto Iglesias, Jeffrey Zhang et al.	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact